| Juvenile polyarthritis
Kevzara vs Cimzia
Side-by-side clinical, coverage, and cost comparison for juvenile polyarthritis.Deep comparison between: Kevzara vs Cimzia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCimzia has a higher rate of injection site reactions vs Kevzara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cimzia but not Kevzara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kevzara
Cimzia
At A Glance
SC injection
Every 2 weeks
IL-6 receptor antagonist
SC injection
Every 2-4 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Polymyalgia Rheumatica
- Juvenile polyarthritis
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis 200 mg SC injection once every 2 weeks; may be used as monotherapy or in combination with methotrexate or other conventional DMARDs.
Polymyalgia Rheumatica 200 mg SC injection once every 2 weeks in combination with a tapering course of corticosteroids; may be used as monotherapy following discontinuation of corticosteroids.
Juvenile polyarthritis 200 mg SC injection once every 2 weeks for patients weighing 63 kg or greater; may be used as monotherapy or in combination with conventional DMARDs.
Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).
Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.
Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.
Contraindications
- Known hypersensitivity to sarilumab or any of the inactive ingredients
- History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)
Adverse Reactions
Most common (>=3%) Neutropenia, increased ALT, injection site erythema, upper respiratory tract infections, urinary tract infections
Serious Serious infections (pneumonia, cellulitis), gastrointestinal perforation, hypersensitivity reactions, neutropenia, thrombocytopenia, elevated liver enzymes, lipid abnormalities
Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)
Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression
Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma
Pharmacology
IL-6 receptor antagonist; sarilumab is a human recombinant IgG1 monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated pro-inflammatory signaling involved in T-cell activation, acute phase protein synthesis, and joint inflammation.
Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kevzara
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Cimzia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Kevzara
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (2/8)
Cimzia
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Humana
Kevzara
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Cimzia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Cimzia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KevzaraView full Kevzara profile
CimziaView full Cimzia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.